Syndax Pharmaceuticals (SNDX) Competitors $15.83 -0.96 (-5.72%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends SNDX vs. AMPH, PTGX, DYN, ENTA, LEGN, ELAN, CYTK, BPMC, NUVL, and LNTHShould you be buying Syndax Pharmaceuticals stock or one of its competitors? The main competitors of Syndax Pharmaceuticals include Amphastar Pharmaceuticals (AMPH), Protagonist Therapeutics (PTGX), Dyne Therapeutics (DYN), Enanta Pharmaceuticals (ENTA), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Blueprint Medicines (BPMC), Nuvalent (NUVL), and Lantheus (LNTH). These companies are all part of the "pharmaceutical products" industry. Syndax Pharmaceuticals vs. Amphastar Pharmaceuticals Protagonist Therapeutics Dyne Therapeutics Enanta Pharmaceuticals Legend Biotech Elanco Animal Health Cytokinetics Blueprint Medicines Nuvalent Lantheus Amphastar Pharmaceuticals (NASDAQ:AMPH) and Syndax Pharmaceuticals (NASDAQ:SNDX) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends. Which has more risk and volatility, AMPH or SNDX? Amphastar Pharmaceuticals has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Syndax Pharmaceuticals has a beta of 0.92, suggesting that its share price is 8% less volatile than the S&P 500. Which has stronger valuation and earnings, AMPH or SNDX? Amphastar Pharmaceuticals has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmphastar Pharmaceuticals$644.40M3.33$137.54M$3.0014.87Syndax Pharmaceuticals$139.71M9.67-$209.36M-$3.63-4.36 Does the MarketBeat Community favor AMPH or SNDX? Amphastar Pharmaceuticals received 9 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 66.33% of users gave Amphastar Pharmaceuticals an outperform vote while only 65.36% of users gave Syndax Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAmphastar PharmaceuticalsOutperform Votes39266.33% Underperform Votes19933.67% Syndax PharmaceuticalsOutperform Votes38365.36% Underperform Votes20334.64% Do insiders and institutionals hold more shares of AMPH or SNDX? 65.1% of Amphastar Pharmaceuticals shares are owned by institutional investors. 27.1% of Amphastar Pharmaceuticals shares are owned by insiders. Comparatively, 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts rate AMPH or SNDX? Amphastar Pharmaceuticals currently has a consensus price target of $63.00, suggesting a potential upside of 41.22%. Syndax Pharmaceuticals has a consensus price target of $36.00, suggesting a potential upside of 127.42%. Given Syndax Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Syndax Pharmaceuticals is more favorable than Amphastar Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amphastar Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Syndax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.91 Is AMPH or SNDX more profitable? Amphastar Pharmaceuticals has a net margin of 21.80% compared to Syndax Pharmaceuticals' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 26.44% beat Syndax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amphastar Pharmaceuticals21.80% 26.44% 11.89% Syndax Pharmaceuticals N/A -64.34%-57.72% Does the media prefer AMPH or SNDX? In the previous week, Syndax Pharmaceuticals had 10 more articles in the media than Amphastar Pharmaceuticals. MarketBeat recorded 15 mentions for Syndax Pharmaceuticals and 5 mentions for Amphastar Pharmaceuticals. Syndax Pharmaceuticals' average media sentiment score of 0.66 beat Amphastar Pharmaceuticals' score of 0.63 indicating that Syndax Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amphastar Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Syndax Pharmaceuticals 3 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAmphastar Pharmaceuticals beats Syndax Pharmaceuticals on 11 of the 18 factors compared between the two stocks. Ad Behind the Markets📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Take these 4 steps to protect your retirement here >>> Get Syndax Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SNDX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNDX vs. The Competition Export to ExcelMetricSyndax PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.35B$6.49B$5.13B$8.74BDividend YieldN/A8.15%5.18%4.07%P/E Ratio-4.364.8266.7313.27Price / Sales9.67374.171,265.2981.14Price / CashN/A51.8140.2135.77Price / Book3.699.636.455.92Net Income-$209.36M$154.43M$119.73M$225.73M7 Day Performance-27.42%-9.46%-5.13%-1.34%1 Month Performance-20.41%-7.27%-2.71%1.15%1 Year Performance3.67%28.13%31.08%24.02% Syndax Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNDXSyndax Pharmaceuticals3.4656 of 5 stars$15.83-5.7%$36.00+127.4%+6.9%$1.35B$139.71M-4.36110Analyst ForecastNews CoverageHigh Trading VolumeAMPHAmphastar Pharmaceuticals4.88 of 5 stars$48.31+4.8%N/A-20.6%$2.35B$644.40M16.101,761Insider SellingPTGXProtagonist Therapeutics3.0657 of 5 stars$46.23-2.9%N/A+155.0%$2.72B$60M17.38125Analyst RevisionDYNDyne Therapeutics3.4781 of 5 stars$28.48-2.7%N/A+190.7%$2.86BN/A-7.93100Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageENTAEnanta Pharmaceuticals3.9626 of 5 stars$11.07-2.5%N/A+9.7%$234.56M$71.96M-2.03145Upcoming EarningsLEGNLegend Biotech1.8575 of 5 stars$40.03-2.2%N/A-39.9%$7.30B$455.99M-51.321,800Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageHigh Trading VolumeELANElanco Animal Health3.5205 of 5 stars$14.07-3.0%N/A+21.5%$6.96B$4.45B-5.529,300Short Interest ↑CYTKCytokinetics4.0709 of 5 stars$57.98+3.8%N/A+58.5%$6.82B$3.22M-10.78250Insider SellingBPMCBlueprint Medicines3.0804 of 5 stars$100.83-0.6%N/A+41.6%$6.41B$249.38M-47.79640Analyst ForecastShort Interest ↑News CoverageNUVLNuvalent3.1126 of 5 stars$95.42+1.4%N/A+49.7%$6.18BN/A-34.3240Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageLNTHLantheus4.6074 of 5 stars$87.50-0.9%N/A+12.7%$6.08B$1.30B14.56834Gap Down Related Companies and Tools Related Companies AMPH Alternatives PTGX Alternatives DYN Alternatives ENTA Alternatives LEGN Alternatives ELAN Alternatives CYTK Alternatives BPMC Alternatives NUVL Alternatives LNTH Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SNDX) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syndax Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syndax Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
